phase trial cisplatin hypertonic saline doses continuous intravenous infusion patients advanced malignancies patients incurable solid tumors Phase trial fixed dose high-dose cisplatin CDDP hypertonic saline doses infusional treatment levels days Leukopenia thrombocytopenia oral mucositis dose-limiting toxicities Nephrotoxicity minimal Ototoxicity peripheral neuropathies rare mild patient group patients small number treatment cycles Diarrhea dose-limiting complete responses non-small cell lung cancer sweat gland carcinoma major responses dose CDDP set consecutive days maximum dose MTD concurrent infusion recommended dosages Phase II trials CDDP consecutive days Cancers lung breast gastrointestinal tract genitourinary tract reasonable targets Phase II studies 